ARBs FDC
Background/Rationale: Ambulatory blood pressure monitoring (ABPM) has been proven to show a closer correlation to prognosis than office blood pressure measurement. Pritor®/Kinzalmono® shows 24-hour efficacy with attenuation of the early morning blood pressure surge when the risk for cardiovascular events is highest.
Objective: To compare the blood lowering effects of PritorPlus®/Kinzalkomb® (telmisartan+HCTZ) and losartan+HCTZ throughout the 24-hour dosing interval using ambulatory blood pressure monitoring (ABPM).
Study Design: ARBs FDC was a 6-week prospective, randomised, open-label, blinded-endpoint (PROBE), multicenter, parallel-group study in hypertensive patients.
Study Endpoints:
- Primary endpoint: change from baseline in SBP during the last 6 hours of the dosing interval using ABPM.
- Secondary endpoint: included trough cuff Blood pressure reductions and other ABPM evaluations.
Results:
- Pritor®/Kinzalmono® provided significantly greater systolic and diastolic blood pressure reductions (SBP and DBP) in the last 6 hours of the dosing interval compared with ramipril at week 14.
- PritorPlus®/Kinzalkomb® provides superior SBP and DBP reductions compared with losartan/HCTZ through the entire 24-hour dosing interval.
Neutel et al. Am J Hypertens 2004;17(5 pt 2):118A.
Conclusion:
In mild-to-moderate hypertensive patients, the ARBs FDC study demonstrated that PritorPlus®/Kinzalkomb® provides superior blood pressure reductions compared to losartan+HCTZ during the early morning period, a time when patients appear to be at greatest risk for cerebro- and cardiovascular events.
